Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 18Neoplasm Metastasis 6Urogenital Neoplasms 1Unilateral Breast Neoplasms 1Recurrence 1Prostatic Neoplasms 1Neoplasms by Site 1Neoplasms 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1HR+/HER2- Breast Cancer 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Breast Cancer Female 1Advanced Breast Cancer 1

Interventions

padeliporfin 3Mitomycin 2valrubicin 1temsirolimus 1pembrolizumab 1palladium-bacteriopheophorbide 1enfortumab vedotin 1abiraterone 1abemaciclib 1Tadalafil 1Standard of Care 1Radiation Dose Hypofractionation 1Prednisone 1Prednisolone 1Phosphodiesterase 5 Inhibitors 1Gemcitabine 1Fluorouracil 1Drug Therapy 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Urogenital Neoplasms × abemaciclib × Clear all
NCT05288166 2025-06-27

CYCLONE 3

Eli Lilly and Company

Phase 3 Active not recruiting
925 enrolled 12 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡